Canagliflozin improves renal outcomes in people with type 2 diabetes mellitus (T2DM) with or at high risk for cardiovascular (CV) disease, according to data recently presented at the 2018 National Kidney Foundation’s Spring Clinical Meetings in Austin, Texas.. This benefit was observed in people with both preserved and reduced kidney function, as measured by estimated...
The demand for kidneys far outstrips the supply. Could offering financial incentives help bridge the gap and save lives?
The evidence is clear: Not taking immune-suppressing meds as prescribed threatens transplanted kidneys. So why do so many patients stray?
